Robert T.M. Van Dongen

Dr. Robert T.M. Van Dongen

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2021 in Pain
Verified
Journal Article
Open access
NKNathaniel Katz
Nathaniel Katz
RDRobert H. Dworkin
Robert H. Dworkin
RNRichard North
Richard North
STSimon Thomson
Simon Thomson
SESam S. Eldabe
Sam S. Eldabe
LVLalit Venkatesan
Lalit Venkatesan
Spinal cord stimulation (SCS) is an interventional nonpharmacologic treatment used for chronic pain and other indications. Methods for evaluating the safety and efficacy of SCS have evolved from uncontrolled and retrospective studies to prospective randomized controlled trials (RCTs). Although randomization overcomes certain types of bias, additional challenges to the validity of RCTs of SCS include blinding, choice of control groups, nonspecific effects of treatment variables (eg, paresthesia, device programming and recharging, psychological support, and rehabilitative techniques), and safety considerations. To address these challenges, 3 professional societies (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials, Institute of Neuromodulation, and International Neuromodulation Society) convened a meeting to develop consensus recommendations on the design, conduct, analysis, and interpretation of RCTs of SCS for chronic pain. This article summarizes the results of this meeting. Highlights of our recommendations include disclosing all funding source and potential conflicts; incorporating mechanistic objectives when possible; avoiding noninferiority designs without internal demonstration of assay sensitivity; achieving and documenting double-blinding whenever possible; documenting investigator and site experience; keeping all information provided to patients balanced with respect to expectation of benefit; disclosing all information provided to patients, including verbal scripts; using placebo/sham controls when possible; capturing a complete set of outcome assessments; accounting for ancillary pharmacologic and nonpharmacologic treatments in a clear manner; providing a complete description of intended and actual programming interactions; making a prospective ascertainment of SCS-specific safety outcomes; training patients and researchers on appropriate expectations, outcome assessments, and other key aspects of study performance; and providing transparent and complete reporting of results according to applicable reporting guidelines.

23 February 2022 in European Addiction Research
Verified
Journal Article
Open access
PDF file
GKGerard Kalkman
Gerard Kalkman
WBWim van Den Brink
Wim van Den Brink
MPMimi Pierce
Mimi Pierce
FAFemke Atsma
Femke Atsma
KVKris C. P. Vissers
Kris C. P. Vissers
ASArnt F. A. Schellekens
Arnt F. A. Schellekens
The past 20 years, the USA is facing a serious opioid crisis initiated by an increase in prescription opioid use. Europe has also seen an increase in prescription opioid use, but the extent of related harm is still largely unknown. Given the impact of the US opioid epidemic, it is important to closely monitor signs of emerging opioid-related problems to guarantee early warnings and timely actions. Shared and meaningful definitions for opioid use and related harms, and relevant information about specific drivers for opioid use and related problems are needed for an adequate policy response. In this commentary, we discuss these definitions, the need to know more about the specific drivers for increased opioid use, its related harm, and proposals for strategies to move forward. Policy recommendations include making a distinction between licit and illicit opioids when monitoring and reporting on opioid-related harm, and using oral morphine equivalents to quantify prescription opioid use in a clinically relevant and comparable manner. A major topic of further research is exploring unique and universal drivers of prescription opioid (mis)use across Europe, in particular the role of opioid diversion.

1 September 2019 in The Journal of Pain
Verified
Journal Article
Closed access
DHDylan Henssen
Dylan Henssen
RWRichard Witkam
Richard Witkam
JDJohan C.M.L. Dao
Johan C.M.L. Dao
DCDaan J. Comes
Daan J. Comes
AWAnne-Marie Van Cappellen van Walsum
Anne-Marie Van Cappellen van Walsum
EKErkan Kurt
Erkan Kurt

18 February 2025 in Pain Practice
Verified
Journal Article
Closed access
THTanja Hamm‐Faber
Tanja Hamm‐Faber
IAInge Arnts
Inge Arnts
DHDylan J. H. A. Henssen
Dylan J. H. A. Henssen
EGEric‐Jan J. A. A. van Gorp
Eric‐Jan J. A. A. van Gorp
FHFrank Van Haren
Frank Van Haren
KVKris C. P. Vissers
Kris C. P. Vissers

13 April 2026 in Pain Practice
Verified
Journal Article
Open access
JCJeroen H. A. Creemers
Jeroen H. A. Creemers
RSRachel J. H. Smits
Rachel J. H. Smits
APAlopi Patel
Alopi Patel
RDRobert T.M. Van Dongen
Robert T.M. Van Dongen
CKCornelis Kramers
Cornelis Kramers
SWSelina E. I. van der Wal
Selina E. I. van der Wal
Background: Pain is a common symptom in palliative care and affects patients' quality of life considerably. Standard analgesics are sometimes insufficient and are associated with substantial side effects. Neurolysis, the targeted destruction of nerves using thermal or chemical agents, offers an additional option for managing localized pain in palliative care. Phenol, a widely available chemical neurolytic agent known for its painless injection and hyperbaric properties when dissolved in glycerin, can effectively relieve refractory cancer pain. Methods: A literature review was conducted on the pharmacology, toxicology, and indications of phenol in interventional pain and palliative medicine. Results: Despite its use as a neurolytic agent for nearly a century, our current understanding of phenol's pharmacological properties, toxicity, and efficacy stems mainly from case series and small studies, often published decades ago. To date, no uniform guidelines exist, nor is there consensus on the optimal application of phenol in clinical practice, resulting in variability among practitioners. Chronic pain syndromes affect up to 30% of the global population, prompting the expansion of phenol neurolysis to new applications, such as joint denervation and sympathetic blocks in non‐cancer pain. Understanding the mechanism of action of phenol and standardizing its clinical use are crucial for integrating this technique into broader pain management strategies. Conclusion: This review provides a comprehensive overview of the mechanisms, indications, benefits, and safety of phenol neurolysis in pain and palliative medicine, aiming to support its evidence‐based use in clinical practice.

13 June 2022 in European journal of pain
Verified
Journal Article
Open access
YPYannick J. G. M. Plantaz
Yannick J. G. M. Plantaz
RDRobert T.M. Van Dongen
Robert T.M. Van Dongen
RWRichard L. Witkam
Richard L. Witkam
KVKris C. P. Vissers
Kris C. P. Vissers
HTHans Timmerman
Hans Timmerman
Background Spinal cord stimulation (SCS) can impact sensory, pain and tolerance thresholds in various ways, which can be accessed via quantitative sensory testing (QST). The objectives of this study were to (1) assess the subjective sensory responses using QST in patients following SCS therapy for PSPS and (2) to get a clinical impression of the results of SCS during an interview of these patients with PSPS and SCS during long term follow-up. Methods Forty patients with PSPS who received SCS treatment underwent QST via electrical and mechanical pressure stimuli. QST was performed at four different moments (1) pre-implantation SCS, (2) two weeks postoperatively, (3) three months after permanent SCS implantation and (4) six months after permanent SCS implantation. Patients' perspectives on pain, use of drugs and quality of life were assessed via semi-structured interviews during a follow-up between 5 and 11 years. Results We found statistical significant differences in the changes of sensory, pain and tolerance thresholds. A decrease in pain complaints and analgesics use were reported by the patients during follow-up. The quality of life in patients increased from three to eight (NRS 0 [worst QoL imaginable] -10 [best QoL imaginable]) after receiving SCS. Conclusions The increased thresholds on areas without pain or being covered by the SCS induced paresthesias may indicate that there are central changes contributing to these deviations in thresholds. The overall QoL in patients improved greatly after receiving SCS. Significance This study provides an overview of the effect of SCS on sensory, pain and tolerance thresholds in patients with PSPS throughout the SCS treatment process. In addition, this study presents data from 40 patients with PSPS treated with SCS, analysing several long-term patient-reported outcome measures. The results serve to give more insight into the mechanism of SCS and document SCS as a possible treatment for PSPS.